期刊文献+

醋酸泼尼松不同方案治疗特发性膜性肾病的效果对照评价 被引量:14

Effects of different options of prednisone acetate for patients with idiopathic membranous nephropathy
原文传递
导出
摘要 目的观察并探讨醋酸泼尼松(Pre)不同方案治疗特发性膜性肾病(Idiopathic membranous nephropathy,IMN)的有效性和安全性。方法选择自2009年2月—2014年2月在义乌市中心医院治疗的IMN患者48例,按照随机数字法将患者分为2组,A组和B组各24例,A组给予Pre联合来氟米特(Leflunomide,LEF)治疗,而B组给予Pre联合环磷酰胺(Cyclophosphamide,CTX)治疗。治疗后统计2组患者的症状缓解情况,治疗前后血肌酐(Serum creatinine,Sr)、24 h尿蛋白定量(24 h Upro)及血浆白蛋白(ALB),以及并发症发生情况。结果 A组缓解率为79.1%(19/24),B组为70.8%(17/24),2组相比,差异不具有统计学意义(P>0.05);2组治疗前Sr、24 h Upro和ALB相比,差异不具有统计学意义(P>0.05);治疗后,2组24 h Upro明显下降,血浆白蛋白明显增加(P<0.05),且2组相比,差异不具有统计学意义(P>0.05);A组并发症率为8.3%(2/24),B组为37.5%(9/24),2组相比,差异具有统计学意义(P<0.05)。结论 LEF联合Pre治疗能明显改善IMN患者的临床症状,疗效显著,且比CTX治疗具有更低的不良反应率,是安全有效的疗法。 Objective To observe the clinical value and safety of different options of prednisone acetate(Pre) for patients with idiopathic membranous nephropathy(IMN). Methods 48 patients with IMN in this hospital since February 2009 to February 2014 were selected, all patients were randomly divided into two groups,24 cases in A group and 24 cases in B group. The group A was treated by Pre combined with LEF, while group B by Pre combined with CTX. After the treatment, the remission of symptoms of both groups was documented. The levels of serum creatinine(Sr) ,24 h urinary protein excre- tion (24 h Upro) and albumin(ALB) were tested, and complications were observed. Results Remission rate was 79.1% (19/24) in A group ,while was 70.8% (17/24) in group B, the difference was not statistically significant (P 〉 0.05 ) ; the difference of Sr,24 h Upro and ALB before treatment between the two groups was not statistically significant (P 〉 0.05 ) ; after treatment, 24 h Upro decreased, ALB increased significantly in both groups ( P 〈 0.05 ) ; complication rate was 8.3% (2/24) in A group, while was 37.5% (9/24) in group B, the difference was statistically significant (P 〈 0.05). Conclusion Pre combined LEF therapy can significantly improve the clinical symptoms of IMN patients, has a significant effect,and a lower rates of adverse reactions when compare with CTX treatment, thus is a safe and effective therapy.
作者 楼红玫
出处 《中华全科医学》 2015年第6期921-923,共3页 Chinese Journal of General Practice
关键词 醋酸泼尼松 来氟米特 环磷酰胺 特发性膜性肾病 Prednisone acetate Leflunomide Cyclophosphamide Idiopathic membranous nephropathy
  • 相关文献

参考文献9

二级参考文献98

共引文献147

同被引文献126

  • 1刘春凤,徐元钊,丁小强,傅辰生,张志刚,郭慕依.特发性膜性肾病预后影响因素[J].复旦学报(医学版),2005,32(2):192-196. 被引量:27
  • 2邬秀娣,孙凌云.小剂量来氟米特治疗类风湿关节炎的远期疗效和安全性[J].江西医药,2005,40(8):435-438. 被引量:1
  • 3梁世凯,许菲菲,舒桂琴,吕吟秋,邵蓉蓉,刘毅.70例特发性膜性肾病的临床特点和治疗探讨[J].中国中西医结合肾病杂志,2006,7(10):595-597. 被引量:9
  • 4王素霞,邹万忠,杨莉,赵明辉.膜性肾病合并IgA肾病的临床病理特点[J].中华病理学杂志,2007,36(3):171-174. 被引量:25
  • 5Classock RJ. Diagnosis and natural course of membranous nephropathy[J]. Semin Nephrol, 2003,23 (4): 324-332.
  • 6Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13 519 renal biopsies[J].Kidney Int,2004,66(4) :920-923.
  • 7Beck LH, Salant DJ. Membranous nephropathy recent travels and new roads ahead[J]. Kidney Int,2010,77(9):765-770.
  • 8Segal PE, Choi MJ. Recent advances and prognosis in idiopathic membranous nephropathy[J]. Adv Chronic Kidney Dis, 2012,19 (2) :114-119.
  • 9Glassoek RJ. Diagnosis and natural course of membranous nephropathy[J]. Semin Nephrol, 2003,23 (4) : 324-332.
  • 10Beck LH Jr, Bouegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009,361 (1) : 11- 21.

引证文献14

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部